Sign In
Buy EXEL
$56.00
+0.94 (+1.71%)
At Close: Aug 04, 2026
Is Exelixis Stock a Buy Now?
01:15pm, Thursday, 29'th Dec 2022 The Motley Fool
Don't be too quick to dismiss this company as a one-trick pony.
Is Exelixis Stock a Buy Now?
08:15am, Thursday, 29'th Dec 2022
Don't be too quick to dismiss this company as a one-trick pony.
2 Top Biotech Stocks to Buy for the Long Haul
01:30pm, Sunday, 25'th Dec 2022 The Motley Fool
These mid-cap biotechs are solid long-term choices.
2 Top Biotech Stocks to Buy for the Long Haul
08:30am, Sunday, 25'th Dec 2022
These mid-cap biotechs are solid long-term choices.
2 Beaten-Down Growth Stocks to Buy Before the Bull Run
01:45pm, Wednesday, 21'st Dec 2022 The Motley Fool
These could become hot buys once investors pivot back to growth stocks.
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
10:21am, Friday, 16'th Dec 2022 The Motley Fool
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.
2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
05:21am, Friday, 16'th Dec 2022
Two drug developers stand out as plain-as-day bargains in the new year, while another top-performing biotech stock looks poised to disappoint.
Nasdaq Bear Market: 5 Exceptionally Cheap Growth Stocks You'll Regret Not Buying on the Dip
10:06am, Saturday, 10'th Dec 2022 The Motley Fool
These bargain-basement-priced growth stocks are ripe for the picking following a 38% peak decline in the Nasdaq Composite.
Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study
07:01pm, Friday, 09'th Dec 2022 Zacks Investment Research
Exelixis (EXEL) announces that the phase III study, CONTACT-01, did not meet its primary endpoint. It also releases initial data from the QUARTZ-101 study.
What 5 Analyst Ratings Have To Say About Exelixis
04:02pm, Friday, 09'th Dec 2022 Benzinga
Exelixis (NASDAQ:EXEL) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
1
0
0
Last 30D
0
1
Where Exelixis Stands With Analysts
03:05pm, Friday, 09'th Dec 2022 Benzinga
Analysts have provided the following ratings for Exelixis (NASDAQ:EXEL) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
3
1
0
0
Last 3
Exelixis (EXEL) Reports Data from CONTACT-01, QUARTZ-101 Study
03:03pm, Friday, 09'th Dec 2022
Exelixis (EXEL) announces that the phase III study, CONTACT-01, did not meet its primary endpoint. It also releases initial data from the QUARTZ-101 study.
3 Stocks to Buy Hand Over Fist in December
12:31pm, Saturday, 03'rd Dec 2022 The Motley Fool
These stocks could be big winners.
3 Stocks to Buy Hand Over Fist in December
07:31am, Saturday, 03'rd Dec 2022
These stocks could be big winners.
Ultragenyx (RARE) Down 0.9% Since Last Earnings Report: Can It Rebound?
04:31pm, Friday, 02'nd Dec 2022 Zacks Investment Research
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
